NASDAQ: QTTBQ32 Bio Inc Stock
$1.56-0.13 (-7.69%)
Updated Apr 29, 2025
QTTB Price
$1.56
Fair Value Price
N/A
Market Cap
$18.97M
52 Week Low
$1.38
52 Week High
$53.79
P/E
-0.3x
P/B
3.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$47.73M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
15.27
Operating Cash Flow
-$68M
Beta
1.08
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
QTTB Overview
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QTTB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QTTB
Ranked#193 of 462
Ranked#193 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important QTTB news, forecast changes, insider trades & much more!
QTTB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QTTB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QTTB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
QTTB is good value based on its book value relative to its share price (3.34x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
QTTB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more QTTB due diligence checks available for Premium users.
Valuation
QTTB fair value
Fair Value of QTTB stock based on Discounted Cash Flow (DCF)
Price
$1.56
Fair Value
$0.60
Overvalued by
158.46%
QTTB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QTTB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
-158.75x
Market
29.19x
QTTB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.34x
Industry
4.37x
QTTB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QTTB's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.2M
Profit Margin
0%
QTTB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$92.3M
Liabilities
$86.7M
Debt to equity
15.27
QTTB's short-term assets ($81.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QTTB's short-term assets ($81.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QTTB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QTTB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.4M
Investing
-$2.0k
Financing
$317.0k
QTTB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QTTB vs Biotech Stocks
Q32 Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.